Published 1 day ago • loading... • Updated 1 day ago

Cipla tops drug overcharging dues with ₹3,576 crore; J&J, Ranbaxy among top five

The government regulates the prices of certain medicines to prevent companies from charging patients more than the permitted amount

1 Articles

The Hindu Business Line

Lean Right

Cipla tops drug overcharging dues with ₹3,576 crore; J&J, Ranbaxy among top five

The government regulates the prices of certain medicines to prevent companies from charging patients more than the permitted amount

1 day ago·Chennai, India

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right1Center0Last Updated1 day agoBias Distribution

100% Right

Bias Distribution

100% of the sources lean Right

100% Right

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Hindu Business Line broke the news in Chennai, India 1 day ago on Monday, November 2, 2026.

Sources are mostly out of (0)

Cipla tops drug overcharging dues with ₹3,576 crore; J&J, Ranbaxy among top five

1 Articles

1 Articles

Cipla tops drug overcharging dues with ₹3,576 crore; J&J, Ranbaxy among top five

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Fifty Years of J&J in Italy, Study: "More Predictability on Payback to Support Investment Innovation"

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

The Cardiorespiratory Arrest After a Thorax Like that of Jesus of Michael: Shock or Heart Contusion?

ISSSTE Is ‘Shielded’ of Protests and Also Promises to Improve in 120 Days: It Will Hire Staff and Rehabilitate Hospitals

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Pfizer Raises 2026 Forecasts After Strong Q3 Results

Similar News Topics

Similar News Topics

More stories like this

Fifty Years of J&J in Italy, Study: "More Predictability on Payback to Support Investment Innovation"

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

The Cardiorespiratory Arrest After a Thorax Like that of Jesus of Michael: Shock or Heart Contusion?

ISSSTE Is ‘Shielded’ of Protests and Also Promises to Improve in 120 Days: It Will Hire Staff and Rehabilitate Hospitals

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Pfizer Raises 2026 Forecasts After Strong Q3 Results

Cipla tops drug overcharging dues with ₹3,576 crore; J&J, Ranbaxy among top five

1 Articles

1 Articles

Cipla tops drug overcharging dues with ₹3,576 crore; J&J, Ranbaxy among top five

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Fifty Years of J&J in Italy, Study: "More Predictability on Payback to Support Investment Innovation"

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

The Cardiorespiratory Arrest After a Thorax Like that of Jesus of Michael: Shock or Heart Contusion?

ISSSTE Is ‘Shielded’ of Protests and Also Promises to Improve in 120 Days: It Will Hire Staff and Rehabilitate Hospitals

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Pfizer Raises 2026 Forecasts After Strong Q3 Results

Similar News Topics

Similar News Topics

More stories like this

Fifty Years of J&J in Italy, Study: "More Predictability on Payback to Support Investment Innovation"

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

The Cardiorespiratory Arrest After a Thorax Like that of Jesus of Michael: Shock or Heart Contusion?

ISSSTE Is ‘Shielded’ of Protests and Also Promises to Improve in 120 Days: It Will Hire Staff and Rehabilitate Hospitals

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Pfizer Raises 2026 Forecasts After Strong Q3 Results

Bias Distribution

Factuality